Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03886948 · ClinicalTrials.gov registry record · Phase 1

A Study of Injections of LY3074828 in Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
66
Enrollment target
1
Study location

NCT03886948 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 66 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03886948, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
66 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to learn about the effects of LY3074828 when given as an injection just under the skin by two different devices. The study will last about 12 weeks for each participant.

Conditions Studied

Interventions

  • DRUG LY3074828
  • DEVICE Pre-filled syringe (PFS)
  • DEVICE Autoinjector (AI)

Study Locations (1)

Florida

  • Covance Clinical Research Inc - Daytona Beach

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2019-03-27
Est. Completion 2019-10-04
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT03886948

The ClinicalTrials.gov registry entry for NCT03886948 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which LY3074828 is the first listed.

NCT03886948 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT03886948 about?

NCT03886948 is a clinical study titled "A Study of Injections of LY3074828 in Healthy Participants". The purpose of this study is to learn about the effects of LY3074828 when given as an injection just under the skin by two different devices. The study will last about 12 weeks for each participant.

What is the current status of trial NCT03886948?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2019-03-27. Estimated completion is 2019-10-04.

What conditions does trial NCT03886948 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT03886948?

The interventions under investigation include: LY3074828 (DRUG), Pre-filled syringe (PFS) (DEVICE), Autoinjector (AI) (DEVICE).

Who is sponsoring clinical trial NCT03886948?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03886948 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.